Allergan USA, Forest Laboratories and Ironwood Pharmaceuticals Inc. have filed a patent infringement suit against a group of pharmaceutical companies trying to bring generic versions of the gastrointestinal drug Linzess to market.
The complaint, filed Wednesday in Delaware District Court, accuses generic drugmakers Teva Pharmaceutical Industries Ltd., Mylan, Sandoz and Aurobindo Pharma of infringing as many as 70 claims of eight patents related to the popular drug, which is used to treat irritable bowel syndrome with constipation and chronic idiopathic constipation.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
